| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stents | 55 | 2018 | 867 | 5.350 |
Why?
|
| Blood Vessel Prosthesis Implantation | 42 | 2019 | 786 | 4.750 |
Why?
|
| Venous Thrombosis | 19 | 2017 | 181 | 3.610 |
Why?
|
| Blood Vessel Prosthesis | 25 | 2018 | 524 | 3.490 |
Why?
|
| Thrombolytic Therapy | 16 | 2017 | 203 | 3.420 |
Why?
|
| Arteriovenous Shunt, Surgical | 11 | 2018 | 94 | 3.080 |
Why?
|
| Carotid Stenosis | 16 | 2018 | 133 | 3.010 |
Why?
|
| Thrombectomy | 16 | 2017 | 102 | 2.810 |
Why?
|
| Vascular Surgical Procedures | 23 | 2018 | 564 | 2.600 |
Why?
|
| Endovascular Procedures | 13 | 2018 | 717 | 2.510 |
Why?
|
| Angioplasty, Balloon | 17 | 2013 | 161 | 2.500 |
Why?
|
| Aortic Aneurysm, Abdominal | 26 | 2012 | 439 | 2.480 |
Why?
|
| Pulmonary Embolism | 9 | 2021 | 172 | 2.360 |
Why?
|
| Endothelium, Vascular | 36 | 2013 | 514 | 2.300 |
Why?
|
| Femoral Artery | 12 | 2017 | 190 | 2.120 |
Why?
|
| Anticoagulants | 17 | 2018 | 585 | 2.070 |
Why?
|
| Fibrinolytic Agents | 12 | 2017 | 199 | 2.040 |
Why?
|
| Heparin | 9 | 2017 | 230 | 1.970 |
Why?
|
| Coated Materials, Biocompatible | 6 | 2017 | 42 | 1.890 |
Why?
|
| Treatment Outcome | 86 | 2021 | 12083 | 1.880 |
Why?
|
| Polytetrafluoroethylene | 8 | 2018 | 80 | 1.870 |
Why?
|
| Endarterectomy, Carotid | 9 | 2018 | 92 | 1.830 |
Why?
|
| Aneurysm, False | 10 | 2008 | 101 | 1.800 |
Why?
|
| Lower Extremity | 9 | 2018 | 178 | 1.800 |
Why?
|
| Carotid Arteries | 6 | 2018 | 151 | 1.680 |
Why?
|
| Renal Dialysis | 11 | 2018 | 842 | 1.670 |
Why?
|
| Vascular Patency | 22 | 2018 | 202 | 1.650 |
Why?
|
| Angioplasty | 12 | 2013 | 85 | 1.640 |
Why?
|
| Ischemia | 11 | 2018 | 344 | 1.610 |
Why?
|
| Embolization, Therapeutic | 9 | 2009 | 225 | 1.570 |
Why?
|
| Arterial Occlusive Diseases | 10 | 2013 | 127 | 1.450 |
Why?
|
| Iliac Vein | 6 | 2017 | 34 | 1.410 |
Why?
|
| Aged | 87 | 2021 | 18998 | 1.390 |
Why?
|
| Iliac Artery | 12 | 2013 | 92 | 1.350 |
Why?
|
| Vascular Diseases | 13 | 2016 | 162 | 1.350 |
Why?
|
| Coronary Vessels | 27 | 2012 | 525 | 1.320 |
Why?
|
| Aorta, Thoracic | 7 | 2019 | 517 | 1.290 |
Why?
|
| Aortic Aneurysm, Thoracic | 9 | 2019 | 653 | 1.270 |
Why?
|
| Time Factors | 32 | 2018 | 6216 | 1.250 |
Why?
|
| Catheterization | 9 | 2018 | 238 | 1.230 |
Why?
|
| Aged, 80 and over | 40 | 2021 | 6343 | 1.190 |
Why?
|
| Carotid Artery Diseases | 7 | 2017 | 147 | 1.190 |
Why?
|
| Male | 125 | 2021 | 59957 | 1.180 |
Why?
|
| Graft Occlusion, Vascular | 8 | 2018 | 95 | 1.170 |
Why?
|
| Upper Extremity | 2 | 2018 | 53 | 1.170 |
Why?
|
| Humans | 216 | 2022 | 122971 | 1.160 |
Why?
|
| Aortography | 12 | 2019 | 200 | 1.150 |
Why?
|
| Thoracic Outlet Syndrome | 2 | 2018 | 12 | 1.140 |
Why?
|
| Endothelial Cells | 22 | 2022 | 529 | 1.130 |
Why?
|
| Middle Aged | 81 | 2021 | 25885 | 1.120 |
Why?
|
| Catheters, Indwelling | 5 | 2018 | 156 | 1.100 |
Why?
|
| Ultrasonic Therapy | 4 | 2017 | 31 | 1.090 |
Why?
|
| Stroke | 11 | 2018 | 957 | 1.030 |
Why?
|
| Aortic Diseases | 6 | 2012 | 197 | 1.020 |
Why?
|
| Prosthesis Design | 16 | 2018 | 667 | 1.010 |
Why?
|
| Aortic Aneurysm | 7 | 2012 | 224 | 1.010 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2016 | 66 | 1.010 |
Why?
|
| Retrospective Studies | 52 | 2021 | 15934 | 1.010 |
Why?
|
| Peripheral Vascular Diseases | 8 | 2011 | 89 | 1.000 |
Why?
|
| Vasodilation | 20 | 2012 | 191 | 1.000 |
Why?
|
| Accidents | 3 | 2018 | 15 | 1.000 |
Why?
|
| Splenic Artery | 3 | 2018 | 22 | 0.990 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2017 | 112 | 0.940 |
Why?
|
| Risk Factors | 36 | 2019 | 9950 | 0.910 |
Why?
|
| Tunica Intima | 6 | 2009 | 59 | 0.870 |
Why?
|
| Catheterization, Central Venous | 3 | 2016 | 131 | 0.870 |
Why?
|
| Vena Cava Filters | 6 | 2017 | 21 | 0.850 |
Why?
|
| Female | 85 | 2021 | 65361 | 0.840 |
Why?
|
| Postoperative Complications | 24 | 2018 | 3002 | 0.820 |
Why?
|
| Risk Assessment | 26 | 2018 | 3319 | 0.800 |
Why?
|
| Angiography | 7 | 2016 | 215 | 0.790 |
Why?
|
| Wounds and Injuries | 3 | 2018 | 363 | 0.780 |
Why?
|
| Laparoscopy | 3 | 2016 | 502 | 0.770 |
Why?
|
| Contusions | 1 | 2021 | 17 | 0.770 |
Why?
|
| Veins | 3 | 2017 | 106 | 0.770 |
Why?
|
| Tomography, X-Ray Computed | 20 | 2021 | 2048 | 0.760 |
Why?
|
| Thrombosis | 7 | 2017 | 520 | 0.740 |
Why?
|
| Lacerations | 1 | 2021 | 34 | 0.740 |
Why?
|
| Kidney Failure, Chronic | 6 | 2016 | 866 | 0.720 |
Why?
|
| Suicide | 2 | 2015 | 175 | 0.710 |
Why?
|
| Decompression, Surgical | 2 | 2018 | 92 | 0.700 |
Why?
|
| Neointima | 3 | 2017 | 43 | 0.690 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 485 | 0.690 |
Why?
|
| Carotid Artery, Common | 5 | 2013 | 73 | 0.680 |
Why?
|
| Radiography, Interventional | 5 | 2016 | 87 | 0.680 |
Why?
|
| Adult | 38 | 2021 | 28944 | 0.670 |
Why?
|
| Device Removal | 5 | 2016 | 223 | 0.670 |
Why?
|
| Vascular Access Devices | 2 | 2017 | 35 | 0.670 |
Why?
|
| Equipment Design | 10 | 2017 | 598 | 0.670 |
Why?
|
| Wounds, Gunshot | 2 | 2015 | 138 | 0.660 |
Why?
|
| Acute Disease | 10 | 2019 | 1092 | 0.650 |
Why?
|
| Aneurysm | 2 | 2018 | 89 | 0.650 |
Why?
|
| Muscle, Smooth, Vascular | 11 | 2011 | 239 | 0.650 |
Why?
|
| Endoscopy | 2 | 2016 | 283 | 0.640 |
Why?
|
| Radiography | 16 | 2014 | 824 | 0.640 |
Why?
|
| Off-Road Motor Vehicles | 1 | 2018 | 4 | 0.640 |
Why?
|
| Coronary Artery Disease | 7 | 2018 | 743 | 0.630 |
Why?
|
| Mechanical Thrombolysis | 2 | 2017 | 10 | 0.630 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2018 | 35 | 0.620 |
Why?
|
| Antioxidants | 12 | 2011 | 341 | 0.610 |
Why?
|
| Peripheral Arterial Disease | 3 | 2017 | 269 | 0.610 |
Why?
|
| Tibial Arteries | 2 | 2017 | 10 | 0.600 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 184 | 0.600 |
Why?
|
| Bioprosthesis | 2 | 2018 | 111 | 0.600 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2007 | 193 | 0.600 |
Why?
|
| Recreation | 2 | 2007 | 18 | 0.590 |
Why?
|
| Lymphocytes | 1 | 2019 | 404 | 0.590 |
Why?
|
| Osteotomy | 1 | 2018 | 39 | 0.590 |
Why?
|
| Ribs | 1 | 2018 | 44 | 0.580 |
Why?
|
| Pelvis | 3 | 2009 | 69 | 0.580 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2010 | 1034 | 0.580 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2017 | 15 | 0.570 |
Why?
|
| Aortic Rupture | 3 | 2012 | 118 | 0.570 |
Why?
|
| Saphenous Vein | 1 | 2017 | 53 | 0.570 |
Why?
|
| Neck Pain | 1 | 2017 | 19 | 0.570 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 312 | 0.570 |
Why?
|
| Altitude | 1 | 2017 | 22 | 0.570 |
Why?
|
| Acute Pain | 1 | 2017 | 20 | 0.570 |
Why?
|
| Aorta, Abdominal | 4 | 2012 | 120 | 0.560 |
Why?
|
| Ritonavir | 8 | 2011 | 54 | 0.560 |
Why?
|
| Swine | 30 | 2012 | 1158 | 0.560 |
Why?
|
| Superoxides | 23 | 2012 | 154 | 0.560 |
Why?
|
| Therapeutic Irrigation | 2 | 2016 | 43 | 0.550 |
Why?
|
| Aorta | 8 | 2008 | 540 | 0.550 |
Why?
|
| Occupations | 1 | 2016 | 21 | 0.550 |
Why?
|
| Music | 1 | 2016 | 15 | 0.540 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 112 | 0.540 |
Why?
|
| Transillumination | 1 | 2016 | 4 | 0.540 |
Why?
|
| Nitric Oxide Synthase Type III | 21 | 2012 | 221 | 0.540 |
Why?
|
| Posture | 2 | 2016 | 153 | 0.530 |
Why?
|
| Travel | 1 | 2017 | 117 | 0.530 |
Why?
|
| Accreditation | 1 | 2016 | 82 | 0.530 |
Why?
|
| Ablation Techniques | 1 | 2016 | 32 | 0.530 |
Why?
|
| Iliac Aneurysm | 2 | 2009 | 31 | 0.530 |
Why?
|
| Atherosclerosis | 11 | 2012 | 828 | 0.520 |
Why?
|
| Varicose Veins | 1 | 2016 | 28 | 0.520 |
Why?
|
| Multivariate Analysis | 10 | 2021 | 1412 | 0.520 |
Why?
|
| Occupational Diseases | 1 | 2016 | 74 | 0.520 |
Why?
|
| Office Visits | 1 | 2016 | 76 | 0.520 |
Why?
|
| Certification | 1 | 2016 | 68 | 0.510 |
Why?
|
| Animals | 65 | 2018 | 33923 | 0.510 |
Why?
|
| Anastomosis, Surgical | 7 | 2007 | 169 | 0.510 |
Why?
|
| Thoracic Injuries | 2 | 2008 | 90 | 0.510 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2017 | 1006 | 0.510 |
Why?
|
| Accidents, Traffic | 4 | 2005 | 101 | 0.510 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 611 | 0.500 |
Why?
|
| Phlebography | 7 | 2017 | 51 | 0.500 |
Why?
|
| Hematoma | 2 | 2007 | 93 | 0.490 |
Why?
|
| Young Adult | 11 | 2021 | 8830 | 0.480 |
Why?
|
| Ultrasonography, Doppler, Duplex | 7 | 2017 | 50 | 0.470 |
Why?
|
| Peritoneal Dialysis | 1 | 2016 | 118 | 0.460 |
Why?
|
| Carotid Artery Injuries | 2 | 2013 | 39 | 0.460 |
Why?
|
| Follow-Up Studies | 22 | 2012 | 5025 | 0.460 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 229 | 0.460 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 213 | 0.460 |
Why?
|
| Catheter-Related Infections | 2 | 2016 | 129 | 0.460 |
Why?
|
| Myocytes, Smooth Muscle | 8 | 2011 | 160 | 0.450 |
Why?
|
| Popliteal Artery | 4 | 2010 | 53 | 0.440 |
Why?
|
| Arginine | 2 | 2007 | 303 | 0.440 |
Why?
|
| Anesthesia, Local | 3 | 2016 | 47 | 0.440 |
Why?
|
| Odds Ratio | 8 | 2017 | 1240 | 0.440 |
Why?
|
| Logistic Models | 9 | 2021 | 1788 | 0.430 |
Why?
|
| Databases, Factual | 5 | 2018 | 1164 | 0.420 |
Why?
|
| Hyperplasia | 8 | 2017 | 215 | 0.420 |
Why?
|
| Computed Tomography Angiography | 3 | 2019 | 195 | 0.410 |
Why?
|
| Homocysteine | 8 | 2008 | 121 | 0.400 |
Why?
|
| Iatrogenic Disease | 3 | 2013 | 132 | 0.400 |
Why?
|
| Vena Cava, Inferior | 4 | 2007 | 100 | 0.390 |
Why?
|
| HIV Infections | 6 | 2011 | 1862 | 0.390 |
Why?
|
| Medical Errors | 1 | 2013 | 155 | 0.390 |
Why?
|
| Transfusion Reaction | 2 | 2013 | 38 | 0.390 |
Why?
|
| Carotid Artery, Internal | 4 | 2007 | 66 | 0.390 |
Why?
|
| Inflammation | 2 | 2017 | 1401 | 0.390 |
Why?
|
| Venous Insufficiency | 3 | 2007 | 12 | 0.380 |
Why?
|
| Autopsy | 4 | 2021 | 118 | 0.380 |
Why?
|
| Limb Salvage | 4 | 2018 | 119 | 0.380 |
Why?
|
| Blood Platelets | 2 | 2004 | 333 | 0.380 |
Why?
|
| Recurrence | 10 | 2016 | 1419 | 0.380 |
Why?
|
| Prosthesis-Related Infections | 4 | 2012 | 176 | 0.370 |
Why?
|
| Splenectomy | 3 | 2008 | 61 | 0.370 |
Why?
|
| Laminectomy | 2 | 2008 | 26 | 0.370 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 37 | 0.360 |
Why?
|
| Renal Artery | 3 | 2008 | 73 | 0.360 |
Why?
|
| Sus scrofa | 7 | 2017 | 122 | 0.360 |
Why?
|
| Texas | 6 | 2017 | 3542 | 0.340 |
Why?
|
| Railroads | 1 | 2009 | 3 | 0.340 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 2104 | 0.340 |
Why?
|
| Oxidative Stress | 16 | 2012 | 804 | 0.340 |
Why?
|
| Angioscopy | 2 | 2009 | 4 | 0.340 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2009 | 38 | 0.330 |
Why?
|
| Atrial Fibrillation | 4 | 2018 | 623 | 0.330 |
Why?
|
| Adolescent | 12 | 2021 | 19043 | 0.330 |
Why?
|
| Catheterization, Peripheral | 2 | 2010 | 126 | 0.330 |
Why?
|
| Pulmonary Artery | 5 | 2011 | 441 | 0.330 |
Why?
|
| Varicocele | 1 | 2009 | 54 | 0.330 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 586 | 0.320 |
Why?
|
| Acute Coronary Syndrome | 2 | 2013 | 198 | 0.320 |
Why?
|
| HIV Protease Inhibitors | 6 | 2011 | 53 | 0.320 |
Why?
|
| Alloys | 3 | 2007 | 16 | 0.320 |
Why?
|
| Mesenteric Vascular Occlusion | 2 | 2008 | 28 | 0.320 |
Why?
|
| Models, Biological | 4 | 2010 | 1440 | 0.320 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2017 | 152 | 0.310 |
Why?
|
| Survival Analysis | 8 | 2007 | 1473 | 0.310 |
Why?
|
| Bradykinin | 11 | 2012 | 57 | 0.310 |
Why?
|
| Surgical Stapling | 1 | 2008 | 17 | 0.300 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 4308 | 0.300 |
Why?
|
| Cholecystostomy | 1 | 2007 | 5 | 0.300 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2007 | 7 | 0.300 |
Why?
|
| Sex Distribution | 4 | 2018 | 286 | 0.300 |
Why?
|
| Incidence | 11 | 2018 | 3040 | 0.300 |
Why?
|
| Play and Playthings | 1 | 2007 | 18 | 0.290 |
Why?
|
| Wounds, Nonpenetrating | 3 | 2005 | 205 | 0.290 |
Why?
|
| Clinical Competence | 7 | 2017 | 977 | 0.290 |
Why?
|
| Age Distribution | 4 | 2018 | 404 | 0.290 |
Why?
|
| Cholecystitis, Acute | 1 | 2007 | 15 | 0.290 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 107 | 0.290 |
Why?
|
| Ligation | 3 | 2018 | 134 | 0.290 |
Why?
|
| Registries | 3 | 2017 | 1381 | 0.290 |
Why?
|
| Thoracic Neoplasms | 1 | 2007 | 36 | 0.290 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2007 | 40 | 0.290 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2007 | 17 | 0.290 |
Why?
|
| Bradycardia | 1 | 2007 | 59 | 0.290 |
Why?
|
| Hematuria | 1 | 2007 | 50 | 0.290 |
Why?
|
| Mesentery | 1 | 2007 | 28 | 0.290 |
Why?
|
| Collateral Circulation | 2 | 2009 | 45 | 0.290 |
Why?
|
| Subclavian Artery | 3 | 2006 | 71 | 0.290 |
Why?
|
| Splenic Diseases | 1 | 2007 | 28 | 0.280 |
Why?
|
| Surgical Instruments | 2 | 2005 | 57 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 1248 | 0.280 |
Why?
|
| Mesenteric Arteries | 1 | 2007 | 57 | 0.280 |
Why?
|
| Cattle | 2 | 2018 | 559 | 0.280 |
Why?
|
| Sports | 1 | 2007 | 59 | 0.280 |
Why?
|
| Prosthesis Failure | 3 | 2006 | 158 | 0.280 |
Why?
|
| Wounds, Penetrating | 1 | 2007 | 139 | 0.280 |
Why?
|
| Transplants | 1 | 2007 | 36 | 0.280 |
Why?
|
| Arteriovenous Fistula | 2 | 2004 | 56 | 0.270 |
Why?
|
| Models, Animal | 8 | 2017 | 467 | 0.270 |
Why?
|
| Blood Loss, Surgical | 1 | 2007 | 146 | 0.270 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 236 | 0.270 |
Why?
|
| Ultrasonography, Doppler | 2 | 2004 | 197 | 0.270 |
Why?
|
| Tyrosine | 4 | 2008 | 166 | 0.270 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 1834 | 0.270 |
Why?
|
| Cell Movement | 6 | 2011 | 838 | 0.260 |
Why?
|
| Surgical Procedures, Operative | 1 | 2008 | 183 | 0.260 |
Why?
|
| Operative Time | 2 | 2017 | 160 | 0.260 |
Why?
|
| Hypotension | 1 | 2007 | 177 | 0.260 |
Why?
|
| Abdominal Injuries | 2 | 2005 | 108 | 0.260 |
Why?
|
| Air Bags | 1 | 2005 | 4 | 0.250 |
Why?
|
| Survival Rate | 9 | 2015 | 1999 | 0.250 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 162 | 0.250 |
Why?
|
| Protective Devices | 1 | 2004 | 8 | 0.240 |
Why?
|
| Kidney | 2 | 2012 | 1346 | 0.240 |
Why?
|
| Central Nervous System Depressants | 2 | 2018 | 24 | 0.240 |
Why?
|
| Dalteparin | 1 | 2004 | 6 | 0.240 |
Why?
|
| Priapism | 1 | 2004 | 10 | 0.240 |
Why?
|
| Colorectal Neoplasms | 2 | 2008 | 562 | 0.230 |
Why?
|
| Seat Belts | 1 | 2004 | 23 | 0.230 |
Why?
|
| Ultrasonography, Interventional | 3 | 2017 | 196 | 0.230 |
Why?
|
| Age Factors | 3 | 2018 | 2799 | 0.230 |
Why?
|
| Bacterial Infections | 1 | 2007 | 305 | 0.230 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2017 | 27 | 0.230 |
Why?
|
| Retinal Artery Occlusion | 1 | 2004 | 17 | 0.220 |
Why?
|
| First Aid | 1 | 2003 | 5 | 0.220 |
Why?
|
| RNA, Messenger | 20 | 2011 | 2833 | 0.220 |
Why?
|
| Wounds, Stab | 1 | 2003 | 38 | 0.220 |
Why?
|
| Ethanol | 2 | 2018 | 163 | 0.220 |
Why?
|
| Ultrasonography | 3 | 2007 | 946 | 0.220 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 1881 | 0.210 |
Why?
|
| Hemorrhage | 3 | 2018 | 459 | 0.210 |
Why?
|
| Ezetimibe | 2 | 2021 | 95 | 0.210 |
Why?
|
| Vasomotor System | 4 | 2009 | 25 | 0.210 |
Why?
|
| Epigastric Arteries | 1 | 2002 | 7 | 0.210 |
Why?
|
| Preoperative Care | 2 | 2009 | 351 | 0.210 |
Why?
|
| Hospitals, Pediatric | 2 | 2018 | 779 | 0.200 |
Why?
|
| Embolism, Cholesterol | 1 | 2002 | 3 | 0.200 |
Why?
|
| Child | 8 | 2021 | 24170 | 0.200 |
Why?
|
| Nitric Oxide | 9 | 2010 | 439 | 0.200 |
Why?
|
| Nephrectomy | 1 | 2003 | 173 | 0.200 |
Why?
|
| Learning | 1 | 2005 | 358 | 0.200 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2008 | 169 | 0.200 |
Why?
|
| Brain Ischemia | 1 | 2004 | 258 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2011 | 94 | 0.200 |
Why?
|
| Tissue Engineering | 7 | 2010 | 178 | 0.200 |
Why?
|
| Patient Safety | 2 | 2016 | 390 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 70 | 0.200 |
Why?
|
| Stress, Mechanical | 5 | 2009 | 171 | 0.200 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2002 | 42 | 0.200 |
Why?
|
| Down-Regulation | 12 | 2012 | 702 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 2011 | 111 | 0.190 |
Why?
|
| Curcumin | 4 | 2005 | 41 | 0.190 |
Why?
|
| Funnel Chest | 1 | 2002 | 34 | 0.190 |
Why?
|
| Hemothorax | 1 | 2021 | 22 | 0.190 |
Why?
|
| Extremities | 1 | 2002 | 82 | 0.190 |
Why?
|
| Cells, Cultured | 16 | 2010 | 3075 | 0.190 |
Why?
|
| In Vitro Techniques | 12 | 2011 | 969 | 0.190 |
Why?
|
| Substance Abuse Detection | 2 | 2013 | 42 | 0.190 |
Why?
|
| Dogs | 2 | 2017 | 770 | 0.190 |
Why?
|
| Viscera | 1 | 2021 | 55 | 0.190 |
Why?
|
| Sternum | 1 | 2021 | 53 | 0.190 |
Why?
|
| Neck Injuries | 1 | 2021 | 23 | 0.190 |
Why?
|
| Narcotics | 2 | 2013 | 63 | 0.190 |
Why?
|
| Masoprocol | 2 | 2011 | 10 | 0.190 |
Why?
|
| General Surgery | 1 | 2003 | 203 | 0.190 |
Why?
|
| Sex Factors | 3 | 2021 | 1246 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 237 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2021 | 713 | 0.190 |
Why?
|
| Pericardial Effusion | 1 | 2021 | 64 | 0.180 |
Why?
|
| Resistin | 4 | 2010 | 36 | 0.180 |
Why?
|
| Patient Selection | 4 | 2008 | 684 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2010 | 672 | 0.180 |
Why?
|
| Warfarin | 2 | 2014 | 120 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2009 | 266 | 0.180 |
Why?
|
| Foreign-Body Migration | 2 | 2016 | 74 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2009 | 256 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2010 | 1689 | 0.180 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2021 | 84 | 0.180 |
Why?
|
| Hemoglobins | 2 | 2013 | 301 | 0.180 |
Why?
|
| Kidney Diseases | 1 | 2004 | 479 | 0.170 |
Why?
|
| Minnesota | 2 | 2021 | 130 | 0.170 |
Why?
|
| Reoperation | 5 | 2012 | 813 | 0.170 |
Why?
|
| Lactosylceramides | 2 | 2009 | 7 | 0.170 |
Why?
|
| Papio | 3 | 2004 | 66 | 0.170 |
Why?
|
| Nitric Oxide Synthase | 11 | 2009 | 186 | 0.160 |
Why?
|
| Fractures, Bone | 1 | 2021 | 181 | 0.160 |
Why?
|
| Femoral Vein | 4 | 2007 | 50 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 431 | 0.160 |
Why?
|
| Confidence Intervals | 3 | 2010 | 277 | 0.160 |
Why?
|
| Midwestern United States | 1 | 2018 | 17 | 0.160 |
Why?
|
| Adenosine Diphosphate | 3 | 2009 | 58 | 0.160 |
Why?
|
| Tramadol | 1 | 2018 | 10 | 0.160 |
Why?
|
| Head Protective Devices | 1 | 2018 | 24 | 0.160 |
Why?
|
| Hypoalbuminemia | 2 | 2011 | 18 | 0.160 |
Why?
|
| Anticholesteremic Agents | 1 | 2021 | 230 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2002 | 528 | 0.160 |
Why?
|
| Thoracotomy | 2 | 2012 | 108 | 0.160 |
Why?
|
| Intraoperative Complications | 3 | 2004 | 174 | 0.150 |
Why?
|
| Heterografts | 1 | 2018 | 183 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2011 | 230 | 0.150 |
Why?
|
| Pressure | 3 | 2008 | 130 | 0.150 |
Why?
|
| Cell Culture Techniques | 6 | 2009 | 288 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 606 | 0.150 |
Why?
|
| Glioma | 1 | 2022 | 497 | 0.150 |
Why?
|
| Mesenteric Veins | 2 | 2008 | 15 | 0.150 |
Why?
|
| Canada | 5 | 2018 | 294 | 0.140 |
Why?
|
| CD40 Ligand | 2 | 2008 | 64 | 0.140 |
Why?
|
| Prospective Studies | 8 | 2008 | 6020 | 0.140 |
Why?
|
| Calcimycin | 2 | 2007 | 26 | 0.140 |
Why?
|
| Constriction, Pathologic | 4 | 2011 | 238 | 0.140 |
Why?
|
| Chronic Disease | 5 | 2011 | 1170 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 3 | 2011 | 211 | 0.140 |
Why?
|
| Medical Records | 1 | 2017 | 189 | 0.140 |
Why?
|
| Hemolysis | 1 | 2017 | 105 | 0.140 |
Why?
|
| Return to Work | 1 | 2016 | 12 | 0.140 |
Why?
|
| Dialysis | 1 | 2016 | 20 | 0.140 |
Why?
|
| Catheter Obstruction | 1 | 2016 | 8 | 0.140 |
Why?
|
| Nitroprusside | 5 | 2009 | 46 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 303 | 0.130 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1301 | 0.130 |
Why?
|
| Retreatment | 1 | 2016 | 88 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 4 | 2013 | 2396 | 0.130 |
Why?
|
| Combined Modality Therapy | 5 | 2007 | 1247 | 0.130 |
Why?
|
| Sclerotherapy | 1 | 2016 | 40 | 0.130 |
Why?
|
| Smoking | 2 | 2017 | 1029 | 0.130 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 94 | 0.130 |
Why?
|
| Hernia, Ventral | 1 | 2016 | 40 | 0.130 |
Why?
|
| Recovery of Function | 2 | 2016 | 437 | 0.130 |
Why?
|
| Severity of Illness Index | 6 | 2013 | 2846 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2016 | 123 | 0.130 |
Why?
|
| Arteries | 5 | 2009 | 222 | 0.130 |
Why?
|
| Immunohistochemistry | 8 | 2011 | 1717 | 0.130 |
Why?
|
| Abdominal Pain | 2 | 2008 | 308 | 0.130 |
Why?
|
| Lysophosphatidylcholines | 2 | 2005 | 13 | 0.130 |
Why?
|
| Biopsy | 1 | 2019 | 1256 | 0.130 |
Why?
|
| Serotonin | 2 | 2007 | 222 | 0.130 |
Why?
|
| Plant Preparations | 2 | 2006 | 18 | 0.130 |
Why?
|
| Research Design | 2 | 2010 | 654 | 0.130 |
Why?
|
| Herniorrhaphy | 1 | 2016 | 80 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 868 | 0.130 |
Why?
|
| Cocaine | 2 | 2009 | 206 | 0.130 |
Why?
|
| Hormones, Ectopic | 2 | 2005 | 10 | 0.130 |
Why?
|
| Ginsenosides | 2 | 2005 | 21 | 0.130 |
Why?
|
| Ginkgo biloba | 2 | 2006 | 13 | 0.130 |
Why?
|
| Phytotherapy | 2 | 2006 | 49 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 254 | 0.120 |
Why?
|
| Thrombomodulin | 2 | 2005 | 24 | 0.120 |
Why?
|
| Probability | 3 | 2004 | 319 | 0.120 |
Why?
|
| Suture Techniques | 2 | 2013 | 199 | 0.120 |
Why?
|
| Firearms | 1 | 2015 | 41 | 0.120 |
Why?
|
| Biomechanical Phenomena | 2 | 2007 | 245 | 0.120 |
Why?
|
| Length of Stay | 3 | 2017 | 1281 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2009 | 210 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 399 | 0.120 |
Why?
|
| Hospitals, Veterans | 2 | 2007 | 355 | 0.120 |
Why?
|
| Lung | 2 | 2021 | 1484 | 0.120 |
Why?
|
| Leg | 3 | 2009 | 155 | 0.120 |
Why?
|
| Cell Division | 5 | 2011 | 793 | 0.110 |
Why?
|
| Vancomycin | 2 | 2013 | 217 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2007 | 405 | 0.110 |
Why?
|
| Vasodilator Agents | 4 | 2010 | 203 | 0.110 |
Why?
|
| Cryopreservation | 2 | 2006 | 82 | 0.110 |
Why?
|
| Cocaine-Related Disorders | 2 | 2007 | 202 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2021 | 13858 | 0.110 |
Why?
|
| New York City | 2 | 2013 | 58 | 0.110 |
Why?
|
| Surgical Wound Infection | 2 | 2013 | 259 | 0.110 |
Why?
|
| Jugular Veins | 1 | 2013 | 75 | 0.110 |
Why?
|
| Prosthesis Implantation | 2 | 2005 | 143 | 0.110 |
Why?
|
| Stem Cells | 2 | 2011 | 713 | 0.110 |
Why?
|
| Transdermal Patch | 1 | 2013 | 7 | 0.110 |
Why?
|
| Blood Pressure | 2 | 2010 | 1317 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3524 | 0.110 |
Why?
|
| Free Radical Scavengers | 2 | 2011 | 49 | 0.110 |
Why?
|
| Acute Kidney Injury | 2 | 2012 | 607 | 0.110 |
Why?
|
| Groin | 1 | 2013 | 15 | 0.110 |
Why?
|
| Intermittent Claudication | 2 | 2011 | 54 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2011 | 836 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2003 | 1158 | 0.110 |
Why?
|
| Polymethyl Methacrylate | 1 | 2012 | 23 | 0.110 |
Why?
|
| Fentanyl | 1 | 2013 | 43 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2009 | 2321 | 0.100 |
Why?
|
| Vasoconstriction | 3 | 2008 | 104 | 0.100 |
Why?
|
| Amputation Stumps | 1 | 2012 | 2 | 0.100 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 70 | 0.100 |
Why?
|
| Glycoproteins | 2 | 2005 | 372 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 4 | 2008 | 138 | 0.100 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2013 | 51 | 0.100 |
Why?
|
| Drug Overdose | 1 | 2013 | 65 | 0.100 |
Why?
|
| Learning Curve | 1 | 2012 | 53 | 0.100 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 75 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2012 | 98 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 439 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 87 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 86 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2007 | 4688 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2012 | 30 | 0.100 |
Why?
|
| Estradiol | 2 | 2005 | 534 | 0.100 |
Why?
|
| Larrea | 1 | 2011 | 5 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 117 | 0.100 |
Why?
|
| Benzyl Alcohols | 1 | 2011 | 13 | 0.100 |
Why?
|
| Antigens, CD | 3 | 2009 | 422 | 0.100 |
Why?
|
| Capillaries | 3 | 2006 | 70 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2011 | 39 | 0.100 |
Why?
|
| Balloon Occlusion | 1 | 2011 | 43 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2011 | 348 | 0.100 |
Why?
|
| Ginkgolides | 1 | 2011 | 9 | 0.090 |
Why?
|
| Masticatory Muscles | 1 | 2011 | 2 | 0.090 |
Why?
|
| Jaw Diseases | 1 | 2011 | 3 | 0.090 |
Why?
|
| United States | 6 | 2010 | 10564 | 0.090 |
Why?
|
| Blood Coagulation | 2 | 2009 | 119 | 0.090 |
Why?
|
| Lactones | 1 | 2011 | 39 | 0.090 |
Why?
|
| Gold | 1 | 2011 | 48 | 0.090 |
Why?
|
| Cholesterol | 2 | 2013 | 522 | 0.090 |
Why?
|
| Metal Nanoparticles | 1 | 2011 | 42 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2013 | 302 | 0.090 |
Why?
|
| Embolectomy | 1 | 2010 | 9 | 0.090 |
Why?
|
| Device Approval | 1 | 2010 | 13 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2009 | 1006 | 0.090 |
Why?
|
| Prognosis | 4 | 2022 | 4503 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2004 | 2025 | 0.090 |
Why?
|
| Recombinant Proteins | 6 | 2010 | 1404 | 0.090 |
Why?
|
| Lipids | 1 | 2013 | 512 | 0.090 |
Why?
|
| Bacterial Translocation | 1 | 2010 | 24 | 0.090 |
Why?
|
| Carotid Sinus | 1 | 2010 | 6 | 0.090 |
Why?
|
| Pressoreceptors | 1 | 2010 | 10 | 0.090 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2010 | 23 | 0.090 |
Why?
|
| Drug-Eluting Stents | 1 | 2010 | 53 | 0.090 |
Why?
|
| Death Certificates | 1 | 2009 | 9 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 240 | 0.090 |
Why?
|
| Forensic Medicine | 1 | 2009 | 12 | 0.090 |
Why?
|
| Electric Injuries | 1 | 2009 | 4 | 0.090 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 62 | 0.080 |
Why?
|
| Impotence, Vasculogenic | 1 | 2009 | 9 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 203 | 0.080 |
Why?
|
| Foam Cells | 1 | 2009 | 20 | 0.080 |
Why?
|
| Paralysis | 1 | 2009 | 35 | 0.080 |
Why?
|
| Water-Electrolyte Balance | 1 | 2010 | 76 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2009 | 43 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 481 | 0.080 |
Why?
|
| DNA Damage | 2 | 2010 | 517 | 0.080 |
Why?
|
| Benzoxazines | 1 | 2009 | 24 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2008 | 193 | 0.080 |
Why?
|
| Lipid Peroxidation | 1 | 2009 | 83 | 0.080 |
Why?
|
| Isoflavones | 1 | 2009 | 44 | 0.080 |
Why?
|
| Blood Vessels | 2 | 2011 | 104 | 0.080 |
Why?
|
| Homicide | 1 | 2009 | 30 | 0.080 |
Why?
|
| Amputees | 1 | 2009 | 9 | 0.080 |
Why?
|
| Chaperonin 60 | 1 | 2009 | 32 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 233 | 0.080 |
Why?
|
| Polyglycolic Acid | 1 | 2009 | 27 | 0.080 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2009 | 34 | 0.080 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 17 | 0.080 |
Why?
|
| Organ Culture Techniques | 2 | 2006 | 155 | 0.080 |
Why?
|
| Gastroepiploic Artery | 1 | 2009 | 2 | 0.080 |
Why?
|
| Capillary Permeability | 1 | 2009 | 78 | 0.080 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2009 | 21 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2009 | 99 | 0.080 |
Why?
|
| Capsaicin | 1 | 2009 | 17 | 0.080 |
Why?
|
| Methadone | 1 | 2009 | 124 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2009 | 70 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 424 | 0.080 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 213 | 0.080 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2008 | 8 | 0.080 |
Why?
|
| Comorbidity | 3 | 2013 | 1491 | 0.080 |
Why?
|
| Protein S | 1 | 2008 | 10 | 0.080 |
Why?
|
| Selenomethionine | 4 | 2012 | 14 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 120 | 0.080 |
Why?
|
| Random Allocation | 2 | 2007 | 417 | 0.080 |
Why?
|
| Serum Amyloid A Protein | 1 | 2008 | 29 | 0.080 |
Why?
|
| Ghrelin | 1 | 2008 | 47 | 0.080 |
Why?
|
| Elective Surgical Procedures | 2 | 2007 | 160 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2009 | 146 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2008 | 54 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2014 | 749 | 0.080 |
Why?
|
| Stockings, Compression | 1 | 2008 | 3 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2009 | 231 | 0.080 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2008 | 4 | 0.080 |
Why?
|
| Duodenal Ulcer | 1 | 2009 | 127 | 0.080 |
Why?
|
| Polyvinyl Alcohol | 1 | 2008 | 10 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2009 | 177 | 0.080 |
Why?
|
| Platinum | 1 | 2008 | 12 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 48 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2008 | 114 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 461 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 181 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2009 | 86 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2008 | 133 | 0.070 |
Why?
|
| Retroperitoneal Space | 1 | 2007 | 19 | 0.070 |
Why?
|
| Thrombin | 1 | 2008 | 60 | 0.070 |
Why?
|
| Cell Differentiation | 5 | 2006 | 1936 | 0.070 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 18 | 0.070 |
Why?
|
| Smad Proteins | 1 | 2008 | 43 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2008 | 558 | 0.070 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 133 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 220 | 0.070 |
Why?
|
| Ceramides | 1 | 2007 | 38 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 45 | 0.070 |
Why?
|
| Carotid Artery, External | 1 | 2007 | 5 | 0.070 |
Why?
|
| Renal Artery Obstruction | 1 | 2007 | 41 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2007 | 97 | 0.070 |
Why?
|
| Leiomyosarcoma | 1 | 2007 | 29 | 0.070 |
Why?
|
| Intraoperative Period | 1 | 2007 | 73 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 127 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 109 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2007 | 136 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 39 | 0.070 |
Why?
|
| Blood Flow Velocity | 2 | 2006 | 448 | 0.070 |
Why?
|
| Gene Expression | 6 | 2009 | 1592 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2007 | 32 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2008 | 143 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 498 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2009 | 450 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2009 | 286 | 0.070 |
Why?
|
| Popliteal Vein | 1 | 2006 | 9 | 0.070 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 1 | 2006 | 4 | 0.070 |
Why?
|
| Endosonography | 1 | 2007 | 82 | 0.070 |
Why?
|
| Atherectomy | 1 | 2006 | 12 | 0.070 |
Why?
|
| Lymphotoxin-alpha | 1 | 2006 | 8 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2009 | 1302 | 0.070 |
Why?
|
| CD40 Antigens | 1 | 2006 | 24 | 0.070 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2012 | 51 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 107 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2006 | 69 | 0.070 |
Why?
|
| Vena Cava, Superior | 1 | 2006 | 55 | 0.070 |
Why?
|
| Blotting, Western | 5 | 2009 | 1106 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 731 | 0.070 |
Why?
|
| alpha-Defensins | 1 | 2006 | 7 | 0.070 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 4 | 2009 | 39 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 5 | 2009 | 1598 | 0.070 |
Why?
|
| Thymosin | 1 | 2006 | 24 | 0.070 |
Why?
|
| Pasteurella multocida | 1 | 2006 | 8 | 0.070 |
Why?
|
| Infant | 1 | 2021 | 12355 | 0.070 |
Why?
|
| Bites and Stings | 1 | 2006 | 30 | 0.060 |
Why?
|
| Plant Extracts | 2 | 2004 | 118 | 0.060 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2006 | 56 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2008 | 670 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2005 | 39 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2006 | 57 | 0.060 |
Why?
|
| Aneurysm, Infected | 1 | 2006 | 25 | 0.060 |
Why?
|
| Streptokinase | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2005 | 38 | 0.060 |
Why?
|
| Albumins | 1 | 2006 | 90 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2006 | 117 | 0.060 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2005 | 40 | 0.060 |
Why?
|
| Biomedical Engineering | 1 | 2005 | 30 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 1151 | 0.060 |
Why?
|
| Superoxide Dismutase | 3 | 2012 | 141 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 254 | 0.060 |
Why?
|
| Infarction | 1 | 2005 | 23 | 0.060 |
Why?
|
| Cell Line | 5 | 2011 | 2787 | 0.060 |
Why?
|
| Filtration | 1 | 2005 | 23 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2006 | 57 | 0.060 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2007 | 341 | 0.060 |
Why?
|
| Coronary Disease | 2 | 2006 | 638 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 230 | 0.060 |
Why?
|
| Forecasting | 2 | 2004 | 355 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2011 | 42 | 0.060 |
Why?
|
| Micropore Filters | 1 | 2004 | 7 | 0.060 |
Why?
|
| Cyclophilin A | 1 | 2005 | 16 | 0.060 |
Why?
|
| Methionine | 1 | 2005 | 102 | 0.060 |
Why?
|
| Intracranial Aneurysm | 1 | 2006 | 93 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 208 | 0.060 |
Why?
|
| Ureteroscopy | 1 | 2004 | 17 | 0.060 |
Why?
|
| Somatostatin | 1 | 2005 | 69 | 0.060 |
Why?
|
| Receptors, Somatostatin | 1 | 2005 | 54 | 0.060 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2005 | 60 | 0.060 |
Why?
|
| Rabbits | 1 | 2006 | 717 | 0.060 |
Why?
|
| Transplantation, Homologous | 2 | 2007 | 660 | 0.060 |
Why?
|
| Electrocoagulation | 1 | 2004 | 37 | 0.060 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2005 | 84 | 0.060 |
Why?
|
| Phosphorylation | 4 | 2010 | 1617 | 0.060 |
Why?
|
| Panax | 1 | 2004 | 8 | 0.060 |
Why?
|
| Macrophages | 1 | 2008 | 613 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2010 | 983 | 0.060 |
Why?
|
| Spleen | 1 | 2005 | 287 | 0.060 |
Why?
|
| Automobile Driving | 1 | 2004 | 27 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 112 | 0.060 |
Why?
|
| Pancreas | 1 | 2005 | 214 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2012 | 715 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2004 | 756 | 0.060 |
Why?
|
| Polypropylenes | 1 | 2003 | 14 | 0.060 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2003 | 4 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2004 | 111 | 0.060 |
Why?
|
| Wine | 1 | 2003 | 15 | 0.060 |
Why?
|
| Leptin | 1 | 2005 | 209 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 259 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 2004 | 123 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 876 | 0.060 |
Why?
|
| Plant Leaves | 1 | 2004 | 43 | 0.060 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2003 | 17 | 0.060 |
Why?
|
| Gene Products, tat | 1 | 2003 | 28 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 282 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2003 | 62 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 55 | 0.050 |
Why?
|
| Subclavian Vein | 1 | 2003 | 23 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2010 | 132 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2010 | 261 | 0.050 |
Why?
|
| Arm | 1 | 2003 | 76 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2011 | 2541 | 0.050 |
Why?
|
| Paraparesis | 1 | 2003 | 11 | 0.050 |
Why?
|
| HIV-1 | 1 | 2007 | 464 | 0.050 |
Why?
|
| Sutures | 1 | 2003 | 67 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 178 | 0.050 |
Why?
|
| Myography | 3 | 2009 | 10 | 0.050 |
Why?
|
| Compartment Syndromes | 1 | 2003 | 31 | 0.050 |
Why?
|
| Hepatic Encephalopathy | 1 | 2003 | 75 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2004 | 142 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 688 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 232 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2007 | 649 | 0.050 |
Why?
|
| Myositis | 1 | 2003 | 51 | 0.050 |
Why?
|
| Physical Examination | 1 | 2003 | 163 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 469 | 0.050 |
Why?
|
| Progesterone | 1 | 2005 | 624 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2009 | 824 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 40 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1680 | 0.050 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2022 | 104 | 0.050 |
Why?
|
| Pacemaker, Artificial | 1 | 2004 | 170 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2022 | 156 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2004 | 172 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2002 | 75 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 1021 | 0.050 |
Why?
|
| Bronchopneumonia | 1 | 2021 | 1 | 0.050 |
Why?
|
| Hypertension | 1 | 2010 | 1276 | 0.050 |
Why?
|
| Luminescent Measurements | 3 | 2005 | 57 | 0.050 |
Why?
|
| Pneumonia, Aspiration | 1 | 2021 | 17 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2022 | 285 | 0.050 |
Why?
|
| Culture Techniques | 3 | 2007 | 91 | 0.050 |
Why?
|
| Reactive Oxygen Species | 3 | 2008 | 483 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 762 | 0.040 |
Why?
|
| Arteriosclerosis | 3 | 2005 | 139 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2009 | 1101 | 0.040 |
Why?
|
| Biomarkers | 4 | 2013 | 2952 | 0.040 |
Why?
|
| Mice | 5 | 2011 | 17647 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 2824 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2021 | 138 | 0.040 |
Why?
|
| RNA | 3 | 2009 | 577 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2021 | 359 | 0.040 |
Why?
|
| Electromyography | 2 | 2011 | 162 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 1222 | 0.040 |
Why?
|
| Catalase | 2 | 2010 | 50 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2011 | 4524 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 93 | 0.040 |
Why?
|
| NADPH Oxidases | 2 | 2009 | 115 | 0.040 |
Why?
|
| Adenosine Triphosphate | 2 | 2010 | 288 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 133 | 0.040 |
Why?
|
| Nanotechnology | 2 | 2009 | 47 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 714 | 0.040 |
Why?
|
| Integrins | 2 | 2008 | 81 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 1586 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 554 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 2 | 2008 | 65 | 0.040 |
Why?
|
| Biocompatible Materials | 2 | 2009 | 123 | 0.040 |
Why?
|
| Mice, Inbred C3H | 2 | 2008 | 119 | 0.040 |
Why?
|
| Tissue Culture Techniques | 2 | 2008 | 70 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2009 | 621 | 0.040 |
Why?
|
| Polyethylene Terephthalates | 2 | 2007 | 40 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2009 | 320 | 0.030 |
Why?
|
| Shear Strength | 2 | 2008 | 17 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2008 | 94 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 144 | 0.030 |
Why?
|
| Collagen | 2 | 2009 | 312 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2009 | 234 | 0.030 |
Why?
|
| Mutation | 1 | 2010 | 5794 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2006 | 42 | 0.030 |
Why?
|
| Umbilical Veins | 2 | 2006 | 74 | 0.030 |
Why?
|
| Guideline Adherence | 2 | 2009 | 375 | 0.030 |
Why?
|
| Perfusion | 2 | 2008 | 197 | 0.030 |
Why?
|
| Endothelial Protein C Receptor | 2 | 2005 | 7 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 520 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 447 | 0.030 |
Why?
|
| beta-Alanine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Dabigatran | 1 | 2014 | 25 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1431 | 0.030 |
Why?
|
| Morpholines | 1 | 2014 | 55 | 0.030 |
Why?
|
| Thiophenes | 1 | 2014 | 60 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2014 | 55 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 100 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2006 | 267 | 0.030 |
Why?
|
| Muscle Contraction | 2 | 2005 | 186 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2014 | 128 | 0.030 |
Why?
|
| Pyridones | 1 | 2014 | 111 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 2029 | 0.030 |
Why?
|
| Azetidines | 1 | 2013 | 55 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 57 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2013 | 6 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 75 | 0.030 |
Why?
|
| Spinal Cord Ischemia | 2 | 2003 | 26 | 0.030 |
Why?
|
| Neoplasms | 1 | 2008 | 2751 | 0.030 |
Why?
|
| Powders | 1 | 2013 | 25 | 0.030 |
Why?
|
| Tobramycin | 1 | 2012 | 23 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 60 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1104 | 0.030 |
Why?
|
| Antisepsis | 1 | 2012 | 10 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2013 | 30 | 0.030 |
Why?
|
| Disarticulation | 1 | 2012 | 2 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 471 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2012 | 144 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2013 | 178 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2013 | 105 | 0.030 |
Why?
|
| Gentamicins | 1 | 2012 | 95 | 0.030 |
Why?
|
| Hip Joint | 1 | 2012 | 38 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2014 | 301 | 0.020 |
Why?
|
| Apoptosis | 2 | 2011 | 1792 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 3299 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2012 | 24 | 0.020 |
Why?
|
| Propensity Score | 1 | 2013 | 203 | 0.020 |
Why?
|
| Cytokines | 2 | 2008 | 1287 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2011 | 106 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 554 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 338 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2011 | 7 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 455 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 89 | 0.020 |
Why?
|
| Equol | 1 | 2009 | 4 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 198 | 0.020 |
Why?
|
| Phytoestrogens | 1 | 2009 | 16 | 0.020 |
Why?
|
| NADPH Oxidase 4 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Caveolin 1 | 1 | 2009 | 46 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1576 | 0.020 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2009 | 11 | 0.020 |
Why?
|
| Alkynes | 1 | 2009 | 26 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 516 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2009 | 23 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2009 | 67 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 73 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2009 | 61 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2009 | 70 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2010 | 320 | 0.020 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2008 | 12 | 0.020 |
Why?
|
| P-Selectin | 1 | 2009 | 77 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 134 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 252 | 0.020 |
Why?
|
| Cholesterol Esters | 1 | 2008 | 14 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 34 | 0.020 |
Why?
|
| U937 Cells | 1 | 2008 | 26 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2009 | 69 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 138 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 41 | 0.020 |
Why?
|
| Anions | 1 | 2008 | 18 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2010 | 354 | 0.020 |
Why?
|
| RNA Stability | 1 | 2009 | 85 | 0.020 |
Why?
|
| Awareness | 1 | 2009 | 81 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 19 | 0.020 |
Why?
|
| Professional Practice | 1 | 2008 | 42 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 353 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2008 | 19 | 0.020 |
Why?
|
| NADP | 1 | 2008 | 48 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2009 | 144 | 0.020 |
Why?
|
| Epinephrine | 1 | 2009 | 174 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 497 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 140 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2007 | 16 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 669 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 245 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2009 | 130 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2007 | 48 | 0.020 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2007 | 43 | 0.020 |
Why?
|
| Renal Veins | 1 | 2007 | 35 | 0.020 |
Why?
|
| Biological Transport | 1 | 2008 | 347 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2010 | 280 | 0.020 |
Why?
|
| E-Selectin | 1 | 2007 | 42 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2009 | 154 | 0.020 |
Why?
|
| Permeability | 1 | 2007 | 118 | 0.020 |
Why?
|
| Replantation | 1 | 2007 | 54 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 100 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 811 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2006 | 77 | 0.020 |
Why?
|
| Portal Vein | 1 | 2007 | 92 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2009 | 232 | 0.020 |
Why?
|
| Credentialing | 1 | 2006 | 18 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2006 | 64 | 0.020 |
Why?
|
| Integrin alpha Chains | 1 | 2006 | 16 | 0.020 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2006 | 9 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 26 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 373 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2006 | 30 | 0.020 |
Why?
|
| Laminin | 1 | 2006 | 59 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 66 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 35 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 429 | 0.020 |
Why?
|
| Flavonoids | 1 | 2006 | 78 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 118 | 0.020 |
Why?
|
| Leukocytes | 1 | 2007 | 207 | 0.020 |
Why?
|
| Regeneration | 1 | 2008 | 205 | 0.020 |
Why?
|
| Selenium Compounds | 1 | 2005 | 3 | 0.020 |
Why?
|
| Nelfinavir | 1 | 2005 | 5 | 0.020 |
Why?
|
| Indinavir | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 817 | 0.020 |
Why?
|
| Saquinavir | 1 | 2005 | 6 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2006 | 93 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 999 | 0.020 |
Why?
|
| Stainless Steel | 1 | 2005 | 6 | 0.020 |
Why?
|
| Furans | 1 | 2005 | 27 | 0.020 |
Why?
|
| Vasculitis | 1 | 2005 | 49 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 243 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 1316 | 0.020 |
Why?
|
| Carbamates | 1 | 2005 | 57 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 454 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2007 | 147 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 1354 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2005 | 56 | 0.020 |
Why?
|
| Integrin alpha4 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 997 | 0.020 |
Why?
|
| Cadaver | 1 | 2005 | 132 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2005 | 44 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 74 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 63 | 0.020 |
Why?
|
| Acetyltransferases | 1 | 2005 | 91 | 0.020 |
Why?
|
| Adiponectin | 1 | 2005 | 109 | 0.010 |
Why?
|
| Oxygen | 1 | 2008 | 550 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 757 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 42 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2005 | 56 | 0.010 |
Why?
|
| Artifacts | 1 | 2005 | 103 | 0.010 |
Why?
|
| Paget Disease, Extramammary | 1 | 2004 | 4 | 0.010 |
Why?
|
| Mitochondria | 1 | 2009 | 684 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 539 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 2005 | 135 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 342 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 1738 | 0.010 |
Why?
|
| Pericardium | 1 | 2005 | 82 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 2003 | 16 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 23 | 0.010 |
Why?
|
| Antibodies | 1 | 2005 | 371 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 313 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 217 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 157 | 0.010 |
Why?
|
| Aging | 1 | 2011 | 1175 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2003 | 51 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 414 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 639 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 377 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2005 | 258 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 186 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2003 | 102 | 0.010 |
Why?
|
| Ion Channels | 1 | 2004 | 187 | 0.010 |
Why?
|
| Culture Media | 1 | 2003 | 183 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1703 | 0.010 |
Why?
|
| Remission Induction | 1 | 2003 | 301 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 710 | 0.010 |
Why?
|
| Embolism | 1 | 2003 | 49 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 821 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1086 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 699 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4392 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 253 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2006 | 510 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 541 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2005 | 848 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 658 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 3342 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1583 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 1045 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 3118 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2004 | 964 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 3888 | 0.010 |
Why?
|
| Veterans | 1 | 2009 | 1721 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 2589 | 0.010 |
Why?
|